Key Takeaways
- Shares of TNGX climbed 45% following announcement of a 92% objective response rate in pancreatic cancer patients receiving vopimetostat combined with daraxonrasib
- The treatment pairing delivered a 100% disease control rate among 12 evaluable patients, with 90% maintaining progression-free status at the 6-month checkpoint
- An alternative combination — vopimetostat paired with zoldonrasib — demonstrated a 52% objective response rate across 27 patients
- Safety profile remained favorable for both combinations; zero Grade 4 or 5 adverse events recorded, with no patients discontinuing treatment
- Company aims to initiate Phase 3 testing of the vopimetostat/daraxonrasib combination for first-line MTAP-deleted pancreatic cancer during the second half of 2026
Shares of Tango Therapeutics (TNGX) surged 45% during Monday’s premarket session following the biotechnology company’s announcement of promising early-stage clinical trial results demonstrating tumor reduction in virtually all advanced pancreatic cancer patients treated with its experimental drug combination.
Tango Therapeutics, Inc., TNGX
The standout figure: a remarkable 92% objective response rate observed in patients receiving vopimetostat alongside Revolution Medicines’ daraxonrasib. This translates to 11 out of 12 evaluable patients with metastatic pancreatic ductal adenocarcinoma experiencing positive responses to therapy.
Additionally, the drug pairing achieved a 100% disease control rate. Of the responses documented, nine of 11 received confirmation, while 90% of participants remained progression-free at the 6-month evaluation point.
The patient population consisted of individuals battling second and third-line metastatic disease — meaning they had undergone previous treatment regimens. More than 70% presented with liver metastases.
As of the May 28 data cutoff, median progression-free survival had not been reached, which typically signals encouraging results during this trial phase.
Trial participants received daily doses of either 200mg or 250mg vopimetostat, combined with 100mg daily daraxonrasib. The dataset encompassed 59 patients total, spanning both pancreatic cancer and non-small cell lung cancer study arms.
Additional Combination Demonstrates Encouraging Results
Tango simultaneously unveiled findings from an alternative drug pairing — vopimetostat combined with Revolution’s zoldonrasib — evaluated in 27 pancreatic cancer patients.
This treatment arm yielded a 52% objective response rate alongside a 74% progression-free survival rate at 6 months. Tumor shrinkage occurred in 14 of the 27 participants.
While these figures don’t match the daraxonrasib combination’s performance, the results reinforce vopimetostat’s therapeutic potential when paired with various partner compounds.
Both treatment combinations exhibited favorable tolerability profiles. The majority of adverse events registered as Grade 1 or 2 severity. Within the daraxonrasib combination group, the most frequently reported side effects included rash, stomatitis/mucositis, and diarrhea. Notably, no Grade 4 or 5 events occurred, and treatment discontinuation due to adverse events was nonexistent.
Future Development Plans
Tango intends to progress the vopimetostat plus daraxonrasib combination into Phase 3 clinical development. The focus: first-line treatment for MTAP-deleted pancreatic cancer patients.
The company anticipates finalizing Phase 3 trial design during the second half of 2026, subject to regulatory consultations.
MTAP deletions are present in approximately 40% of pancreatic cancer cases and roughly 15% of lung cancer diagnoses — establishing a well-defined patient subset that provides clear genetic selection parameters for trial enrollment.
These findings arrive just one week following Revolution Medicines’ presentation of daraxonrasib data at ASCO, where the compound demonstrated doubled survival rates in pancreatic cancer patients.
Tango’s vopimetostat represents an orally administered therapeutic specifically engineered to target malignant cells harboring MTAP deletions.
Revolution Medicines (RVMD) stock declined 4.15% during the trading session.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
